化学科研者一站式服务平台
化合物简介
Daclatasvir (USAN, formerly BMS-790052, trade name Daklinza) is a drug for the treatment of hepatitis C (HCV). It was developed by Bristol-Myers Squibb and was approved in Europe on 22 August 2014. Daklinza gained its FDA approval on July 24, 2015 in the United States; it is approved for Hepatitis C genotype 3 infections.
基本信息
CAS：1009119-64-5
中文别名：N,N\'-[[1,1\'-联苯]-4,4\'-二基双[1H-咪唑-5,2-二基-(2S)-2,1-吡咯烷二基 [(1S)-1-(1-甲基乙基)-2-氧代-2,1-乙烷二基]]]双氨基甲酸 C,C\'-二甲酯;
英文别名：Carbamic acid, N,N\'-[[1,1\'-biphenyl]-4,4\'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C\'-dimethyl ester;N,N\'-[[1,1\'-Biphenyl]-4,4\'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C\'-dimethyl ester;BMS-790052;EBP 883;Daclatasvir;
分子式：C40H50N8O6
分子量：738.875
精确质量：738.385
Psa：174.64
Logp：6.8796
中文别名：N,N\'-[[1,1\'-联苯]-4,4\'-二基双[1H-咪唑-5,2-二基-(2S)-2,1-吡咯烷二基 [(1S)-1-(1-甲基乙基)-2-氧代-2,1-乙烷二基]]]双氨基甲酸 C,C\'-二甲酯;
英文别名：Carbamic acid, N,N\'-[[1,1\'-biphenyl]-4,4\'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C\'-dimethyl ester;N,N\'-[[1,1\'-Biphenyl]-4,4\'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C\'-dimethyl ester;BMS-790052;EBP 883;Daclatasvir;
分子式：C40H50N8O6
分子量：738.875
精确质量：738.385
Psa：174.64
Logp：6.8796
编号系统
UNII：LI2427F9CI
物化性质
密度：1.249